4D Molecular Therapeutics, Inc. (FDMT)
收市後：
| 前收市價 | 21.70 |
| 開市 | 21.71 |
| 買盤 | 0.00 x 900 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 21.01 - 21.87 |
| 52 週波幅 | 5.32 - 26.49 |
| 成交量 | |
| 平均成交量 | 508,178 |
| 市值 | 704.211M |
| Beta 值 (5 年，每月) | 2.56 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.79 |
| 業績公佈日 | 2023年3月27日 - 2023年3月31日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 37.57 |
- Benzinga
BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target'
BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ: FDMT) with an Outperform rating and a price target of $50. The analyst writes that 4DMT's platform has generated competitive gene therapies and been clinically validated through its five ongoing clinical programs. BMO notes that 4D Molecular Therapeutics' Wet Age-Related Macular Degeneration (wet AMD) program addresses key limitations of approved/investigational therapies and can potentially confer a $5 billion oppo
- Benzinga
4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial
4D Molecular Therapeutics Inc (NASDAQ: FDMT) announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD). 4D-150 was safe and well tolerated, with no serious adverse events or dose-limiting toxicities reported. No clinically significant intraocular inflammation, endophthalmitis, retinal vasculitis, retinal artery occlusion, choroidal effusions, and hypotony were reported to date. Also see: 4D Molecular Shares Fall
- Benzinga
4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment
4D Molecular Therapeutics Inc (NASDAQ: FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing Phase 1/2 trial of 4D-310 for Fabry disease. The protocol amendment is intended to expand the eligible patient population, including the addition of female Fabry patients with symptomatic disease. SVB Securities cuts 4D Molecular to Market Perform from Outperform with a price target of $12, down from $28 after the Fabry update. The analyst feels this decision is an
